As per DelveInsight’s assessment, the Liver Cirrhosis Market is expected to grow in the coming years owing to the increasing prevalent population of Hepatic Cirrhosis in the 7MM, improving health care infrastructure, new product launches, government support for clinical development, and the launch of the emerging therapies.
Companies all over 7MM are persistently working towards the development of novel treatment therapies that can address Hepatic Cirrhosis. There are several promising drugs in the pipeline, including Terlipressin (Mallinckrodt), Belapectin (Galectin Therapeutics), among others.
DelveInsight’s “Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Liver Cirrhosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Liver Cirrhosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Liver Cirrhosis Overview
Hepatic Cirrhosis is a late-stage liver disease in which healthy liver tissue is replaced with scar tissue, and the liver is permanently damaged.
In the developed world, the most common causes of cirrhosis are hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH), while hepatitis B virus (HBV) and HCV are the most common causes in the developing world. Other causes of cirrhosis include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver cirrhosis, chronic right-sided heart failure.
Liver Cirrhosis Market Key Facts
-
The total market size of Liver Cirrhosis in the 7MM was around USD 3 billion in 2022 which is estimated to increase by 2032 at a significant CAGR.
-
Liver cirrhosis is a chronic and progressive liver disease characterized by the replacement of healthy liver tissue with scar tissue estimated to affect nearly 3.5 million people in 2022 in the 7MM.
-
Liver cirrhosis is a significant health issue in the United States, and its prevalence has been increasing over the past few decades. According to DelveInsight estimates, among the 7MM, the US has the most cases of Liver Cirrhosis followed by Japan, Germany, and Italy in 2022.
-
The market size of liver cirrhosis is influenced by various factors such as the pharmaceuticals and treatment options available for managing the condition, prevalence of liver cirrhosis, advancements in treatment options, healthcare infrastructure, and reimbursement policies. As per DelveInsight research, based on historical data, the US consistently captured the highest market among the 7MM, whereas Spain had the lowest market. The market size of liver cirrhosis was estimated to be around USD 2 billion in the US in 2022 and nearly USD 75 million in Spain.
-
In the 7MM, the United States is expected to account for the largest share of the global market due to the favorable reimbursement scenario, an increase in R&D investments in pharmaceutical companies & research institutes for new drug development, and the presence of major players in the region.
-
Europe is likely to be the second-largest market for liver cirrhosis treatment during the forecast period due to the rise in awareness about new treatment options and develop a regulatory framework.
-
According to a study by Scaglione et al. (2015), the prevalence of cirrhosis in the United States was approximately 0.27%, corresponding to 633,300+ adults over the age of 18.
-
According to the National Center for Biotechnology Information (NCBI), the liver disease accounts for nearly 2 million deaths per year globally; 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma. Cirrhosis is currently the 11th most common cause of death globally, and liver cancer is the 16th leading cause of death; combined, these account for 3.5% of all global deaths.
-
On Jan. 05, 2023, Galectin Therapeutics, Inc. (NASDAQ: GALT) announced that in late December 2022, it ended enrollment of NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). NAVIGATE is the first study of its kind and is a global effort that recruited patients in 14 countries and on five continents.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Liver Cirrhosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Liver Cirrhosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Liver Cirrhosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Liver Cirrhosis Epidemiology, Segmented by –
-
Total Prevalent cases of Hepatic Cirrhosis (2019–2032)
-
Gender-specific cases of Hepatic Cirrhosis (2019–2032)
-
Age-specific cases of Hepatic Cirrhosis (2019–2032)
-
Etiology-specific cases of Hepatic Cirrhosis (2019–2032)
Liver Cirrhosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Cirrhosis market or expected to be launched during the study period. The analysis covers the Liver Cirrhosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Liver Cirrhosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Liver Cirrhosis Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/liver-cirrhosis-market
Liver Cirrhosis Therapeutics Analysis
Several major pharma and biotech giants are persistently working towards the development of novel treatment therapies that can address Hepatic Cirrhosis. Currently, CymaBay Therapeutics is leading the therapeutics market with its Liver Cirrhosis drug candidates in the most advanced stage of clinical development.
Leading Companies in the Liver Cirrhosis Market Include:
-
CymaBay Therapeutics
-
Mirum Pharmaceuticals
-
Pharmicell Co., Ltd.
-
Can-Fite BioPharma
-
Genfit
-
SHIONOGI & Co.
-
COUR Pharmaceutical
-
Zydus Therapeutics Inc
-
Genkyotex SA
-
Gannex Pharma Co., Ltd.
-
Novartis
-
HighTide Biopharma Pty Ltd
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
-
GlaxoSmithKline
-
Ohara Pharmaceutical
-
Pliant Therapeutics
-
MYR Pharmaceuticals
-
Active Biotech
-
Future Medicine Co., Ltd.
-
Dr. Falk Pharma GmbH
-
Suzhou Zelgen Biopharmaceuticals
-
And Many More
Liver Cirrhosis Therapies Covered in the Report Include:
-
Seladelpar: CymaBay Therapeutics
-
Volixibat: Mirum Pharmaceuticals
-
Belapectin (GR-MD-02): Galectin Therapeutics
-
Terlipressin: Mallinckrodt
-
And Many Others
Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/liver-cirrhosis-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Liver Cirrhosis Competitive Intelligence Analysis
4. Liver Cirrhosis Market Overview at a Glance
5. Liver Cirrhosis Disease Background and Overview
6. Liver Cirrhosis Patient Journey
7. Liver Cirrhosis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Liver Cirrhosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Liver Cirrhosis Unmet Needs
10. Key Endpoints of Liver Cirrhosis Treatment
11. Liver Cirrhosis Marketed Products
12. Liver Cirrhosis Emerging Drugs and Latest Therapeutic Advances
13. Liver Cirrhosis Seven Major Market Analysis
14. Attribute Analysis
15. Liver Cirrhosis Market Outlook (In US, EU5, and Japan)
16. Liver Cirrhosis Access and Reimbursement Overview
17. KOL Views on the Liver Cirrhosis Market
18. Liver Cirrhosis Market Drivers
19. Liver Cirrhosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Other Trending Healthcare Reports By DelveInsight
Liver Cirrhosis Pipeline Insight
“Liver Cirrhosis – Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 50+ drugs in the Liver Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/